Viridian Therapeutics, Inc./DE Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
Viridian Therapeutics, Inc./DE (VRDN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -5.70% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-26
- Viridian Therapeutics, Inc./DE effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was -5.70%.
- Viridian Therapeutics, Inc./DE effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was -0.40%.
- Viridian Therapeutics, Inc./DE effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was -1.50%.
- Viridian Therapeutics, Inc./DE effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2021 was -2.30%, a 1250.00% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2024-12-31 | -5.70% 10-K · filed 2026-02-26 |
| 2023-12-31 | -0.40% 10-K · filed 2026-02-26 |
| 2022-12-31 | -1.50% 10-K · filed 2025-03-03 |
| 2021-12-31 | -2.30% 10-K · filed 2024-02-27 |
| 2020-12-31 | 0.20% 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |